BioSyent Releases Financial Results for Q3 and YTD 2024
BioSyent Releases Financial Results for Q3 and YTD 2024
The CEO's presentation on the Q3 and YTD 2024 Results is available at the following link: MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2024. Key highlights include:
加拿大安大略省密西沙加，2024年11月20日(GLOBE NEWSWIRE) -- BioSyent Inc.("BioSyent"，tsx创业公司: RX) 今日发布了截至2024年9月30日为止的三个月(Q3)和九个月(YTD)财务业绩。主要亮点包括：
| (CAD) | Q3 2024 |
% Change vs. Q3 2023 |
YTD 2024 |
% Change vs. YTD 2023 |
Trailing Twelve Months (TTM) Sept 30, 2024 |
% Change vs. TTM Sept 30, 2023 |
||||||
| Canadian Pharma Sales | 8,303,074 | +12% | 24,384,698 | +13% | 32,373,796 | +12% | ||||||
| Total Company Sales | 9,556,011 | +8% | 26,234,213 | +13% | 34,507,899 | +12% | ||||||
| EBITDA1 | 2,849,636 | -2% | 7,101,900 | +13% | 8,752,201 | +12% | ||||||
| Net Income After Taxes (NIAT) | 2,307,894 | -2% | 5,656,910 | +13% | 7,107,701 | +14% | ||||||
| Fully Diluted EPS | 0.20 | -% | 0.48 | +17% | 0.60 | +18% |
| (加元) | 2024年第三季度 | 变动百分比 vs。 Q3 2023 |
2024年迄今 | 涨幅相对于 2023年迄今 |
过去十二个月截至2024年9月30日 | 涨幅相对于 TTm Sept 30, 2023 |
||||||
| 加拿大药品销售 | 8,303,074 | +12% | 24,384,698 | +13% | 32,373,796 | +12% | ||||||
| 公司总销售额 | 9,556,011 | +8% | 26,234,213 | +13% | 34,507,899 | +12% | ||||||
| EBITDA1 | 2,849,636 | -2% | 7,101,900 | +13% | 8,752,201 | +12% | ||||||
| 净利润税后（NIAT） | 2,307,894 | -2% | 5,656,910 | +13% | 7,107,701 | +14% | ||||||
| 全摊薄每股收益 | 0.20 | -% | 0.48 | +17% | 0.60 | +18% |
- Return on Average Equity for TTM September 30, 2024 was 20% as compared to 18% for TTM September 30, 2023
- During YTD 2024, repurchased for cancellation a total of 162,300 common shares under a Normal Course Issuer Bid (NCIB)
- Paid quarterly cash dividends of $0.045 per common share on March 15, 2024, June 15, 2024, and September 15, 2024
- Declared subsequent cash dividend of $0.045 per common share to be paid on December 16, 2024
- During Q3 2024, acquired Tibelia / Tibella - tibolone ("Tibelia") global rights, related assets, and operating business
- Tibelia acquisition expected to generate revenue and incremental EBITDA starting in Q1 2025
- 2024年9月30日TTm的平均资产回报率为20%，而2023年9月30日TTm的平均资产回报率为18%
- 在2024年度至今，根据正常课程发行者竞标(NCIB)，共回购了162,300股普通股用于注销
- 于2024年3月15日、6月15日和9月15日分别按每普通股0.045美元的价格支付季度现金分红
- 宣布在2024年12月16日支付每普通股0.045美元的随后现金股息
- 在2024年第三季度，收购了Tibelia / Tibella - 勃龙酮（"Tibelia"）的全球权利，相关资产和营业
- 预计Tibelia收购将在2025年第一季度开始产生营收和逐步EBITDA增长
"We are pleased to report our highest-ever quarterly total Company sales in Q3 2024 with 8% growth over the comparative Q3 2023 and 7% growth over the prior quarter, Q2 2024," said René Goehrum, President and CEO of BioSyent. "With 12% sales growth in Canadian pharmaceutical sales, all of the Company's Canadian pharmaceutical products contributed to this growth during the quarter. On a year-to-date basis, our total Company sales, EBITDA and NIAT all grew by 13%. On a per share basis, as a result of our ongoing share buybacks, diluted EPS increased by 17% to $0.48 for the year-to-date period."
"我们很高兴地宣布，在2024年第三季度，BioSyent总公司销售额创下历史新高，较2013年第三季度增长8%，较上一季度2024年第二季度增长7%，"BioSyent的总裁兼CEO雷内·戈伊尔姆先生说。"在加拿大药品销售方面，销售增长12%，公司的所有加拿大药品产品在本季度均有贡献。按年度计算，我们的总公司销售额、EBITDA和净利润分别增长了13%。每股基础上，由于我们不断进行的回购，摊薄后每股收益已经增长了17%，达到了0.48美元。"
Mr. Goehrum continued, "While we continued to deliver profitable growth during the quarter, we also made investments in future growth with continued promotion of our three in-market launch products, FeraMAX Pd Maintenance 45, Inofolic, and Gelclair, as well as development of a new FeraMAX Pd product and regulatory support of a new endocrinology product in-licensed earlier this year. During the quarter, we also made a significant investment in acquiring Tibelia at an attractive valuation. We continue to transition this business to our operating structure and look forward to shipping product in Q1 2025 to fill existing customer orders. With the revenue and EBITDA we expect the Tibelia business to generate, the capital deployed in this transaction delivers on our strategic objectives of long-term growth and portfolio diversification. I look forward to reporting on our continued progress during the rest of 2024 and 2025."
戈伊尔姆先生继续说道，"尽管在本季度继续保持盈利增长，我们还在未来增长方面进行了投资，不仅继续推广我们三个在市场上推出的产品，FeraMAX Pd Maintenance 45、Inofolic和Gelclair，还开发了新的FeraMAX Pd产品以及此前授权的新内分泌学产品的监管支持。在本季度，我们还进行了一笔重大投资，以有吸引力的估值收购Tibelia。我们将继续将这项业务转移到我们的营运结构，并期待在2025年第一季度发货以填补现有客户订单。随着我们期望Tibelia业务产生的营收和EBITDA，这笔交易中部署的资本实现了我们的长期增长和组合多样化战略目标。我期待在2024年和2025年的其余时间继续报告我们的进展。"
The CEO's presentation on the Q3 and YTD 2024 Results is available at the following link:
首席执行官关于2024年第三季度和年至今2024年结果的演示可在以下链接找到：
The Company's Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three and nine months ended September 30, 2024 and 2023 will be posted on on November 20, 2024.
公司的截至2024年9月30日和2023年9月30日的三个月和九个月的中期未经审计的简明合并财务报表和管理层讨论与分析将于2024年11月20日发布。
For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit .
About BioSyent Inc.
关于BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.
BioSyent在tsx交易所上市，交易标的为"RX"，是一家有盈利的增长性专业药品公司。该公司专注于入许可证或收购已成功开发、安全有效、有证据证明可以改善病患生活的药品和其他保健产品。BioSyent通过其社区、专业和国际业务部门将其产品推销给医疗保健专业人员，帮助他们治疗病人。
As of the date of this press release, the Company has 11,594,101 common shares outstanding.
截至本新闻稿发布之日，公司共有11,594,101股普通股流通。
| BioSyent Inc. | ||||||||||||||
| Interim Unaudited Condensed Consolidated Statements of Comprehensive Income | ||||||||||||||
| In Canadian Dollars | Q3 2024 | Q3 2023 | % Change | YTD 2024 | YTD 2023 | % Change | ||||||||
| Net Revenues | 9,556,011 | 8,871,122 | 8% | 26,234,213 | 23,316,616 | 13% | ||||||||
| Cost of Goods Sold | 2,069,596 | 1,809,024 | 14% | 5,533,089 | 4,423,178 | 25% | ||||||||
| Gross Profit | 7,486,415 | 7,062,098 | 6% | 20,701,124 | 18,893,438 | 10% | ||||||||
| Operating Expenses and Finance Income/Costs | 4,511,311 | 3,999,903 | 13% | 13,169,535 | 12,214,323 | 8% | ||||||||
| Net Income Before Tax | 2,975,104 | 3,062,195 | -3% | 7,531,589 | 6,679,115 | 13% | ||||||||
| Tax (including Deferred Tax) | 667,210 | 711,295 | -6% | 1,874,679 | 1,669,779 | 12% | ||||||||
| Net Income After Tax | 2,307,894 | 2,350,900 | -2% | 5,656,910 | 5,009,336 | 13% | ||||||||
| Net Income After Tax % to Net Revenues | 24% | 27% | 22% | 21% | ||||||||||
| EBITDA | 2,849,636 | 2,899,612 | -2% | 7,101,900 | 6,276,177 | 13% | ||||||||
| EBITDA % to Net Revenues | 30% | 33% | 27% | 27% | ||||||||||
| 1. EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization. | ||||||||||||||
| BioSyent公司 | ||||||||||||||
| 8,944,566 | ||||||||||||||
| 1,466,192 | 2024年第三季度 | Q3 2023 | 变更百分比 | 2024年迄今 | 2023年迄今 | 变更百分比 | ||||||||
| 净收入 | 9,556,011 | 8,871,122 | 8% | 26,234,213 | 23,316,616 | 13% | ||||||||
| 销售成本 | 2,069,596 | 1,809,024 | 14% | 5,533,089 | 4,423,178 | 25% | ||||||||
| 毛利润 | 7,486,415 | 7,062,098 | 6% | 20,701,124 | 18,893,438 | 10% | ||||||||
| 7% | 4,511,311 | 3,999,903 | 13% | 13,169,535 | 12,214,323 | 8% | ||||||||
| 2,975,104 | 3,062,195 | -3% | 7,531,589 | 6,679,115 | 13% | |||||||||
| 10% | 667,210 | 711,295 | -6% | 1,874,679 | 1,669,779 | 12% | ||||||||
| 2,307,894 | 2,350,900 | -2% | 5,656,910 | 5,009,336 | 13% | |||||||||
| BioSyent Inc. | 24% | 27% | 22% | 21% | ||||||||||
| EBITDA | 2,849,636 | 2,899,612 | -2% | 7,101,900 | 6,276,177 | 13% | ||||||||
| -34% | 30% | 33% | 27% | 27% | ||||||||||
| 1. EBITDA是一种非IFRS财务指标。EBITDA一词在国际财务报告准则（IFRS）下没有任何标准化含义，因此可能与其他公司提供的类似指标不可比。公司将EBITDA定义为利息收入或费用、所得税、折旧和摊销前的收益。 | ||||||||||||||
| BioSyent Inc. | ||||||
| Interim Unaudited Condensed Consolidated Statements of Financial Position | ||||||
| AS AT | September 30, 2024 | December 31, 2023 | % Change | |||
| ASSETS | ||||||
| Cash, cash equivalents and short-term investments | $ | 17,064,865 | $ | 26,187,011 | -35% | |
| Trade and other receivables | 4,342,441 | 3,477,096 | 25% | |||
| Inventory | 5,659,593 | 5,894,495 | -4% | |||
| Prepaid expenses and deposits | 391,940 | 243,460 | 61% | |||
| Loans receivable - current | 68,917 | 69,419 | -1% | |||
| Derivative asset | 22,252 | - | ||||
| CURRENT ASSETS | 27,550,008 | 35,871,481 | -23% | |||
| Long term investments | 10,496,713 | 2,500,000 | 320% | |||
| Property and equipment | 1,254,710 | 1,439,930 | -13% | |||
| Intangible assets | 5,711,094 | 1,152,876 | 395% | |||
| Loans receivable - non current | 156,926 | 205,182 | -24% | |||
| Deferred tax asset | 301,224 | 359,470 | -16% | |||
| TOTAL NON CURRENT ASSETS | 17,920,667 | 5,657,458 | 216% | |||
| TOTAL ASSETS | $ | 45,470,675 | $ | 41,528,939 | 9% | |
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
| CURRENT LIABILITIES | $ | 7,034,216 | $ | 5,533,850 | 27% | |
| NON CURRENT LIABILITIES | 1,090,207 | 1,235,333 | -12% | |||
| Long term debt | - | - | 0% | |||
| Total Equity | 37,346,252 | 34,759,756 | 7% | |||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 45,470,675 | $ | 41,528,939 | 9% | |
| BioSyent公司 | ||||||
| 截至 | 2024年9月30日 | 2023年12月31日 | 变更百分比 | |||
| 资产 | ||||||
| 向我们的收益金额在扣除支出之前，不考虑事先执行已获得附权证或普通权证。 | $ | 17,064,865 | $ | 26,187,011 | -35% | |
| 应收账款及其他 | 4,342,441 | 25% | ||||
| 存货 | 5,659,593 | -4% | ||||
| 预付费用和存款 | 391,940 | 61% | ||||
| 157,479 | 68,917 | 69,419 | -1% | |||
| 衍生工具资产 | 22,252 | - | ||||
| 流动资产 | 27,550,008 | -23% | ||||
| 长期投资 | 10,496,713 | 2,500,000 | ||||
| 物业及设备 | 1,254,710 | -13% | ||||
| 无形资产 | 5,711,094 | 395% | ||||
| - | 156,926 | -24% | ||||
| 递延所得税资产 | 301,224 | -16% | ||||
| 41,478,376 | 17,920,667 | For further information please contact: | 216% | |||
| 资产总计 | $ | 45,470,675 | $ | 本新闻发布可能包含前瞻性信息或表述。本文所载内容仅代表我们在发布日期的判断，并可能面临风险和不确定性，这可能导致实际结果或结局与前瞻性信息或表述有重大不同。潜在风险可能包括但不限于与临床试验、产品开发、未来营业收入、业务运营、盈利能力和获得监管批准有关的事项。TSX创业公司交易所及其监管服务提供商（如TSX创业公司交易所政策中定义的那一术语）对本新闻发布的充分性或准确性不负责任。 | 9% | |
| 负债和股东权益 | ||||||
| 流动负债 | $ | 7,034,216 | $ | 5,533,850 | 27% | |
| 非流动负债 | 1,090,207 | 1,235,333 | -12% | |||
| 开多期债务 | - | - | 0% | |||
| 总权益 | 37,346,252 | 34,759,756 | 7% | |||
| 资产负债合计 | $ | 45,470,675 | $ | 本新闻发布可能包含前瞻性信息或表述。本文所载内容仅代表我们在发布日期的判断，并可能面临风险和不确定性，这可能导致实际结果或结局与前瞻性信息或表述有重大不同。潜在风险可能包括但不限于与临床试验、产品开发、未来营业收入、业务运营、盈利能力和获得监管批准有关的事项。TSX创业公司交易所及其监管服务提供商（如TSX创业公司交易所政策中定义的那一术语）对本新闻发布的充分性或准确性不负责任。 | 9% | |
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web:
要了解更多信息，请联系：
Rene C. Goehrum先生
董事长兼首席执行官
BioSyent公司
电子邮件：investors@biosyent.com
电话：905-206-0013
网站:
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
本新闻稿可能包含前瞻性的信息或声明。所述内容仅代表我们在发布日期的判断，并可能存在风险和不确定性，导致实际结果与前瞻性信息或声明有实质性差异。潜在风险可能包括但不限于与临床试验、产品研发、未来收入、运营、盈利能力和获得监管批准有关的风险。TSX Venture Exchange及其监管服务提供商（根据TSX Venture Exchange政策的定义）对本新闻稿的充分性或准确性不承担责任。
